# TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY

> **NIH NIH R01** · ROSWELL PARK CANCER INSTITUTE · 1990 · $100,780

## Abstract

Monoclonal antibody F36/22 (IgG3, recognizes a glycoprotein with Mr of 700-
1000k) has been shown immunohistochemically to be reactive with all human
common epithelial ovarian cancers, while normal ovary expresses no
detectable level of immunostain.  Human exfoliated ovarian tumor cells are
usually disseminating throughtout the entire peritoneal cavity, and
represent an ideal target for therapeutic manipulation in a confined
compartment.  A recently available human ovarian carcinoma xenograft in
female athymic mice, NIH:OVCAR-3, expresses antigen recognized by monoclonal
antibody F36/22 and resembles the human disease by producing ascites and
intra-abdominal carcinomatosis.  Using monoclonal antibody F36/22 as the
probe and NIH:OVCAR-3 as the in vivo model, we will develop and evaluate
effective radioimmunotherapy for the targeting and elimination of peritoneal
ovarian tumor seedings.  Adriamycin, a commonly used cytotoxic agent in
ovarian cancer, will be conjugated to monoclonal antibody F36/22 for
intracavity immunochemotherapy of ovarian tumor.  Effectiveness of both
therapies will be potentiated by biological response modifiers.  The
proposed approaches to the use of a unique monoclonal antibody in targeting
and therapy of ovarian cancer in a confined cavity compartment with little
or no communication with other body compartments will generate defined and
useful preclinical information.  Additionally, data available most recently
have suggested the targeting of a repetitive epitope on a breast cancer
mucin by McAb F36/22, which was initially generated against human breast
cancer cell lines.  Since antibody reagent is already available, an
immunoassy can be developed easily and evaluated most efficiently on the
association between McAb F36/22 and the breast cancer mucin, and the result
will be compared with that obtained from an ovarian cancer mucin previously
reported by us.  Finally, we will elucidate the antigenic determinant(s) of
the human prostate specific antigen (PSA), originally reported from this
laboratory and the most effective and FDA approved marker for managment of
prostate cancer, in order to increase the efficacy of tumor
targeting/therapy by monoclonal antibodies already generated.

## Key facts

- **NIH application ID:** 3175437
- **Project number:** 5R01CA037646-06
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE
- **Principal Investigator:** Tsann Ming Chu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1990
- **Award amount:** $100,780
- **Award type:** 5
- **Project period:** 1984-08-15 → 1992-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3175437

## Citation

> US National Institutes of Health, RePORTER application 3175437, TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY (5R01CA037646-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3175437. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*